Market Research Logo

Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Summary


Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma to very common conditions such as acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control it can significantly impair the patient’s quality of life. For example, patients with severe atopic dermatitis may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, disease visibility can have a profoundly negative impact on patient confidence.

Dermatological conditions are some of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active condition. Although dermatological diseases are disparate in terms of their symptoms and key patient demographics, many are characterized by increased inflammation and linked by an aberrant immune response resulting in skin barrier dysfunction. Infections and dysfunctions in wound healing are further common causes of dermatological diseases.

For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the long-term use of many available treatments. Various treatment options exist within the therapy area, including topical glucocorticosteroids, retinoids, antihistamines and immunosuppressive agents, all of which are heavily genericized. The majority of marketed products within dermatology are small molecules, which account for 98.2% of all products. There are only a small number of other more novel molecule types, such as monoclonal antibodies (mAb), proteins and cell therapies, available in the market.

Overall, the dermatology pipeline is considerably innovative, owing to the advancements in understanding of the disease pathways of many skin disorders. Analysis by molecular target highlights that there is a strong degree of innovation and diversity beyond the current market landscape. There is a clear emphasis, demonstrated particularly by biologics in mid-to-late stage clinical development, on developing effective targeted therapies aimed at key molecules in disease pathology, which represents an innovative approach that will benefit the market in the coming years. On the other hand, therapeutic molecular target classes that are already present in the market – such as histamine receptors, retinoic acid receptors, glucocorticoid receptors, and tumor necrosis factor – also maintain a presence in the pipeline, which indicates that developing established therapeutic classes remains attractive.

The report “Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation” is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report provides the following analysis -

  • Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
  • Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
  • Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.
Companies mentioned in this report: Bristol-Myers Squibb, Pfizer, Nimbus Therapeutics, Sareum, Genentech, Portola Pharmaceuticals, Oncostellae.

Scope
  • With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market?
  • There are 197 first-in-class products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • The majority of first-in-class products are in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
  • A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
Reasons to buy
  • Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
  • Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
  • Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.


  • Executive Summary
    • Large Therapy Area Characterized by a High Degree of Pathophysiological Crossover
    • Biologics and mAbs Growing in Prominence in Dermatology Therapy Area
    • Highly Diversified Range of Innovative Programs in Early Pipeline
    • Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products Landscape
  • The Case for Innovation
    • Table Figure 1: Dermatology Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014
    • Growing Opportunities for Biologic Products
    • Diversification of Molecular Targets
    • Innovative First-in-Class Development Remains Attractive
      • Table Figure 2: Dermatology Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013
    • Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
    • Sustained Innovation
    • GBI Research Report Guidance
  • Clinical and Commercial Landscape
    • Therapy Area Introduction
    • Symptoms
      • Table Dermatology Therapeutics Market, Main Symptoms of Atopic Dermatitis, Acne Vulgaris and Psoriasis, 2017
    • Epidemiology and Etiology
      • Table Dermatology Therapeutics Market, Global, Epidemiology of Dermatological Disorders, 2017
      • Atopic Dermatitis
      • Acne Vulgaris
      • Psoriasis
    • Pathophysiology
      • Atopic Dermatitis
      • Acne Vulgaris
      • Psoriasis
    • Co-morbidities and Complications
    • Treatment
      • Topical Corticosteroids
      • Calcineurin Inhibitors
      • Retinoids
      • Systemic Immunosuppressive Agents
      • Biologics
      • Antihistamines
      • Hormonal Therapy
      • Moisturizers
    • Overview of Marketed Products in Dermatology
      • Table Figure 3: Dermatology Therapeutics Market, Global, Marketed Products by Molecule Type, 2017
      • Table Figure 4: Dermatology Therapeutics Market, Global, Marketed Products by Molecular Target, 2017
  • Assessment of Pipeline Product Innovation
    • Pipeline by Stage of Development, Molecule Type and Molecular Target
      • Table Figure 5: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
      • Table Figure 6: Dermatology Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2017
      • Table Figure 7: Dermatology Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2017
    • First-in-Class Programs Targeting Novel Molecular Targets
      • Table Figure 8: Dermatology Therapeutics Market, Global, Distribution of Pipeline First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target, 2017
      • Table Figure 9: Dermatology Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development (%), 2017
      • Table Figure 10: Dermatology Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017
      • Table Figure 11: Dermatology Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development, 2017
      • Table Figure 12: Dermatology Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Molecular Target, 2017
      • Table Figure 13: Dermatology Therapeutics Market, Global, Pipeline Products, 2017
  • Signaling Network, Disease Causation and Innovation Alignment
    • Complexity of Signaling Networks in Dermatology
    • Signaling Pathways and First-in-Class Molecular Target Integration
    • First-in-Class Matrix Assessment
      • Table Figure 28: Dermatology Therapeutics Market, Global, First-in-Class Matrix Assessment (Inflammatory Diseases), 2017
      • Table Figure 33: Dermatology Therapeutics Market, Global, First-in-Class Matrix Assessment (Infectious Diseases), 2017
      • Table Figure 34: Dermatology Therapeutics Market, Global, First-in-Class Matrix Assessment (Wounds/Scars), 2017
  • First-in-Class Target and Pipeline Program Evaluation
    • Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2
      • Table Dermatology Therapeutics Market, Global, Key Features and Pipeline Activity of Non-Receptor Tyrosine-Protein Kinase TYK2, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2, 2017
    • Pipeline Programs Targeting Granzyme B
      • Table Dermatology Therapeutics Market, Global, Key Features of Granzyme B, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Granzyme B, 2017
    • Pipeline Programs Targeting ORAI1
      • Table Dermatology Therapeutics Market, Global, Key Features of ORAI1, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting ORAI1, 2017
    • Pipeline Programs Targeting CC motif chemokine 11
      • Table Dermatology Therapeutics Market, Global, Key Features and Pipeline Activity of CCL11, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting CCL11, 2017
    • Pipeline Programs Targeting Potassium Voltage-Gated Channel Subfamily A Member 3
      • Table Dermatology Therapeutics Market, Global, Key Features and Pipeline Activity of Voltage-Gated Channel Subfamily A Member 3, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Voltage-Gated Channel Subfamily A Member 3, 2017
    • Pipeline Programs Targeting Toll-like Receptor 8
      • Table Dermatology Therapeutics Market, Global, Key Features of TLR8, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting TLR8, 2017
    • Pipeline Programs Targeting CC Chemokine Receptor Type 6
      • Table Dermatology Therapeutics Market, Global, Key Features of CC Chemokine Receptor Type 6, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting CC Chemokine Receptor Type 6, 2017
    • Pipeline Programs Targeting Targeting Spleen Tyrosine Kinase
      • Table Dermatology Therapeutics Market, Global, Key Features of Spleen Tyrosine Kinase, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Spleen Tyrosine Kinase, 2017
    • Pipeline Programs Targeting Galectin-3
      • Table Dermatology Therapeutics Market, Global, Key Features and Pipeline Activity of Galectin-3, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Galectin-3, 2017
    • Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 6
      • Table Dermatology Therapeutics Market, Global, Key Features of Tumor Necrosis Factor Receptor Superfamily Member 6, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 6, 2017
    • Pipeline Programs Targeting Sphingosine 1- phosphate receptor 4
      • Table Dermatology Therapeutics Market, Global, Key Features of Sphingosine 1-Phosphate Receptor 4, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Sphingosine 1-Phosphate Receptor 4, 2017
    • Pipeline Programs Targeting Protein-Lysine 6- Oxidase
      • Table Dermatology Therapeutics Market, Global, Key Features of Protein Lysine 6 Oxidase, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Protein Lysine 6 Oxidase, 2017
    • Pipeline Programs Targeting Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6
      • Table Dermatology Therapeutics Market, Global, Key Features of Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6, 2017
      • Table Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6, 2017
    • Conclusion
  • Strategic Consolidations
    • Industry-Wide First-in-Class Deals
      • Table Figure 35: Dermatology Therapeutics Market, Global, Industry-Wide Deals by Stage of Development and First-in-Class Status, 2006-2014
      • Table Figure 36: Dermatology Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2014
    • Licensing Deals
      • Deals by Region, Value and Year
        • Table Figure 37: Dermatology Therapeutics Market, Global, Licensing Deals by Region, Value and Year, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 38: Dermatology Therapeutics Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 39: Dermatology Therapeutics Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006-2017
        • Table Figure 40: Dermatology Therapeutics Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006-2017
      • List of Deals with Disclosed Deal Values
        • Table Figure 41: Dermatology Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017
    • Codevelopment Deals
      • Deals by Region, Value and Year
        • Table Figure 43: Dermatology Therapeutics Market, Global, Co-development Deals by Region, Value and Year, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 44: Dermatology Therapeutics Market, Global, Codevelopment
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 45: Dermatology Therapeutics Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006-2017
        • Table Figure 46: Dermatology Therapeutics Market, Global, Number of Co-development Deals by Molecular Target, 2006-2017
      • List of Deals with Disclosed Deal Values
        • Table Figure 47: Dermatology Therapeutics Market, Global, Co-development Deals with Disclosed Deal Values, 2006-2017
    • First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals
      • Table Figure 48: Dermatology Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Codevelopment Deals, 2017
      • Table Figure 49: Dermatology Therapeutics Market, Global, First-in-Class Pipeline Products with No Disclosed Prior Involvement in Licensing or Co-development Deals, 2017
  • Appendix
    • References
    • Abbreviations
    • Research Methodology
    • Secondary Research
      • Market Analysis
      • Pipeline Analysis
      • First-in-Class Matrix Assessment
      • First-in-Class Target Profiles
      • Licensing and Co-Development Deals
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report